<p>Emerging evidence underscores biophysical characteristics of cancer cells as key modulators of cancer progression and metastasis. Herein, we reported a cell-mechanophenotyping screening microfluidic chip (termed LesM) for the high-efficient capture of circulating tumor cells (CTCs) and evaluation of single-cell deformation to reveal the hematogenous metastatic potential of bacteria-infected breast cancer. LesM employs L-shaped traps to capture single cells, leveraging bacteria-infected CTCs with cytoskeletal reorganization traverse narrowed channels while rigid native cells are retained. The platform demonstrates an average single-cell capture efficiency of 95.42% and specificity of 85.34% in discriminating infected versus non-infected breast cancer cells, validated through parallel in vivo metastatic assays. LesM enables high-throughput sensing up to 10,240 cells of mechanical signatures and microbial cargo, correlating with metastatic risk and antibiotic response. By bridging biomechanics and intratumoral microbiota detection, LesM offers a transformative liquid biopsy tool for predicting distant metastasis and guiding antimicrobial therapies in bacteria-infected breast cancers.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

A Mechanophenotyping chip for high-throughput detection of metastatic bacteria-infected circulating tumor cells

  • Wen Luo,
  • Yanfeng Gao,
  • Shujun Feng,
  • Bangshun He,
  • Jingjing Li,
  • Jingjing Yang,
  • Yi Yin,
  • Meng Wang,
  • Bin Xue,
  • Yi Cao,
  • Tony Y. Hu,
  • Yujun Song

摘要

Emerging evidence underscores biophysical characteristics of cancer cells as key modulators of cancer progression and metastasis. Herein, we reported a cell-mechanophenotyping screening microfluidic chip (termed LesM) for the high-efficient capture of circulating tumor cells (CTCs) and evaluation of single-cell deformation to reveal the hematogenous metastatic potential of bacteria-infected breast cancer. LesM employs L-shaped traps to capture single cells, leveraging bacteria-infected CTCs with cytoskeletal reorganization traverse narrowed channels while rigid native cells are retained. The platform demonstrates an average single-cell capture efficiency of 95.42% and specificity of 85.34% in discriminating infected versus non-infected breast cancer cells, validated through parallel in vivo metastatic assays. LesM enables high-throughput sensing up to 10,240 cells of mechanical signatures and microbial cargo, correlating with metastatic risk and antibiotic response. By bridging biomechanics and intratumoral microbiota detection, LesM offers a transformative liquid biopsy tool for predicting distant metastasis and guiding antimicrobial therapies in bacteria-infected breast cancers.